• Something wrong with this record ?

Alzheimer's disease and other neurodegenerative dementias in comorbidity: A clinical and neuropathological overview

R. Matej, A. Tesar, R. Rusina,

. 2019 ; 73 (-) : 26-31. [pub] 20190807

Language English Country United States

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc19044593

Neuropathological diagnostic criteria of neurodegenerative disorders are based on the presence of specific inclusions in a specific area of brain tissue that correlate with clinical manifestations. Concomitant neurodegenerative disorders correspond to a combination of two (or more) different fully developed diseases in the same patient. Concomitant neurodegenerative pathology represents the presence of definite neurodegeneration and deposits of pathological proteins specific for another disease, which is not, however, fully developed. Very frequent overlaps include Alzheimer's disease and alpha-synuclein inclusions. Nevertheless, careful neuropathological investigations reveal an increasing frequency of different co-pathologies in examined brains. In Alzheimer's disease, protein TDP-43 may co-aggregate, but it is not clear whether this is atypical isolated Alzheimer's disease or overlap of Alzheimer's disease with early frontotemporal lobar degeneration. Comorbidities of Alzheimer's disease and tauopathies are relatively rare. A combination of vascular pathology with primary neurodegeneration (mostly Alzheimer's disease or dementia with Lewy bodies) is historically called mixed dementia. Overlap of different neuropathologically confirmed neurodegenerations could lead to atypical and unusual clinical presentations and may be responsible for faster disease progression. Several CSF biomarkers have been evaluated for their utility in diagnostic processes in different neurodegenerative dementias; however, evidence regarding their role in neurodegenerative overlaps is still limited.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19044593
003      
CZ-PrNML
005      
20200113081031.0
007      
ta
008      
200109s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.clinbiochem.2019.08.005 $2 doi
035    __
$a (PubMed)31400306
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Matej, Radoslav $u Department of Pathology and Molecular Medicine, Third Faculty of Medicine, Charles University, Thomayer Hospital, Prague, Czech Republic; Department of Pathology, First Faculty of Medicine, Charles University, General University Hospital, Prague, Czech Republic.
245    10
$a Alzheimer's disease and other neurodegenerative dementias in comorbidity: A clinical and neuropathological overview / $c R. Matej, A. Tesar, R. Rusina,
520    9_
$a Neuropathological diagnostic criteria of neurodegenerative disorders are based on the presence of specific inclusions in a specific area of brain tissue that correlate with clinical manifestations. Concomitant neurodegenerative disorders correspond to a combination of two (or more) different fully developed diseases in the same patient. Concomitant neurodegenerative pathology represents the presence of definite neurodegeneration and deposits of pathological proteins specific for another disease, which is not, however, fully developed. Very frequent overlaps include Alzheimer's disease and alpha-synuclein inclusions. Nevertheless, careful neuropathological investigations reveal an increasing frequency of different co-pathologies in examined brains. In Alzheimer's disease, protein TDP-43 may co-aggregate, but it is not clear whether this is atypical isolated Alzheimer's disease or overlap of Alzheimer's disease with early frontotemporal lobar degeneration. Comorbidities of Alzheimer's disease and tauopathies are relatively rare. A combination of vascular pathology with primary neurodegeneration (mostly Alzheimer's disease or dementia with Lewy bodies) is historically called mixed dementia. Overlap of different neuropathologically confirmed neurodegenerations could lead to atypical and unusual clinical presentations and may be responsible for faster disease progression. Several CSF biomarkers have been evaluated for their utility in diagnostic processes in different neurodegenerative dementias; however, evidence regarding their role in neurodegenerative overlaps is still limited.
650    _2
$a Alzheimerova nemoc $x metabolismus $x patologie $7 D000544
650    _2
$a biologické markery $x metabolismus $7 D015415
650    _2
$a DNA vazebné proteiny $x metabolismus $7 D004268
650    _2
$a lidé $7 D006801
650    _2
$a demence s Lewyho tělísky $x metabolismus $x patologie $7 D020961
650    _2
$a patologická konformace proteinů $x metabolismus $x patologie $7 D066263
650    _2
$a alfa-synuklein $x metabolismus $7 D051844
650    _2
$a proteiny tau $x metabolismus $7 D016875
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Tesar, Adam $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University, General University Hospital, Prague, Czech Republic.
700    1_
$a Rusina, Robert $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University, General University Hospital, Prague, Czech Republic; Department of Neurology, Third Faculty of Medicine, Charles University, Thomayer Hospital, Prague, Czech Republic. Electronic address: robert.rusina@lf1.cuni.cz.
773    0_
$w MED00001119 $t Clinical biochemistry $x 1873-2933 $g Roč. 73, č. - (2019), s. 26-31
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31400306 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200109 $b ABA008
991    __
$a 20200113081403 $b ABA008
999    __
$a ok $b bmc $g 1482862 $s 1083266
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 73 $c - $d 26-31 $e 20190807 $i 1873-2933 $m Clinical biochemistry $n Clin Biochem $x MED00001119
LZP    __
$a Pubmed-20200109

Find record

Citation metrics

Archiving options